The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Desferal     N-[5-[3-(5-aminopentyl- hydroxy...

Synonyms: Desferan, Desferex, Desferin, Desferral, deferoxamine, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Deferrioxamine B


Psychiatry related information on Deferrioxamine B


High impact information on Deferrioxamine B


Chemical compound and disease context of Deferrioxamine B


Biological context of Deferrioxamine B

  • Significantly lower doses of deferoxamine were being taken by patients without abnormalities than by those with visual symptoms, abnormal audiograms, or prolonged evoked potentials (P less than 0.001, less than 0.006, and less than 0.04, respectively) [3].
  • Beginning chelation treatment with deferoxamine before the age of puberty can help children with transfusion-dependent thalassemia major to attain normal sexual maturation [18].
  • The half-life of NOS mRNA appeared not to be significantly altered by administration of ferric ion, and NOS mRNA stability was only slightly prolonged by desferrioxamine treatment [19].
  • Both compounds activate NOS by limiting the availability of iron: their stimulating effects on NO synthesis and inhibiting action on cell proliferation are reverted by iron supplementation with ferric nitrilotriacetate, and are mimicked by incubation with desferrioxamine [20].
  • These macromolecular forms of deferoxamine do not cause detectable decreases in blood pressure of experimental animals, even when administered intravenously in very large doses, and persist in circulation much longer than the free drug [21].

Anatomical context of Deferrioxamine B


Associations of Deferrioxamine B with other chemical compounds


Gene context of Deferrioxamine B


Analytical, diagnostic and therapeutic context of Deferrioxamine B


  1. Intravenous or subcutaneous deferoxamine for iron overload? Kramer, P. N. Engl. J. Med. (1978) [Pubmed]
  2. Deferoxamine in thalassemia major. Splendiani, G., Tozzo, C., Mazzarella, V., Casciani, C.U. N. Engl. J. Med. (1995) [Pubmed]
  3. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. Olivieri, N.F., Buncic, J.R., Chew, E., Gallant, T., Harrison, R.V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B. N. Engl. J. Med. (1986) [Pubmed]
  4. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. Praga, M., Enriquez de Salamanca, R., Andres, A., Nieto, J., Oliet, A., Perpiña, J., Morales, J.M. N. Engl. J. Med. (1987) [Pubmed]
  5. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M.H., Nathan, D.G. N. Engl. J. Med. (1985) [Pubmed]
  6. Intramuscular desferrioxamine in patients with Alzheimer's disease. Crapper McLachlan, D.R., Dalton, A.J., Kruck, T.P., Bell, M.Y., Smith, W.L., Kalow, W., Andrews, D.F. Lancet (1991) [Pubmed]
  7. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity. Altmann, P., Dhanesha, U., Hamon, C., Cunningham, J., Blair, J., Marsh, F. Lancet (1989) [Pubmed]
  8. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Treadwell, M.J., Weissman, L. Semin. Hematol. (2001) [Pubmed]
  9. Chelation therapy in beta-thalassemia: an optimistic update. Giardina, P.J., Grady, R.W. Semin. Hematol. (2001) [Pubmed]
  10. Evaluation of cerebral vasospasm with transcranial magnetic stimulation: an experimental study. Göksel, H.M., Akgün, M., Topalkara, K., Solak, O., Topaktaş, S. Clin. Exp. Med. (2001) [Pubmed]
  11. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. Olivieri, N.F., Brittenham, G.M., McLaren, C.E., Templeton, D.M., Cameron, R.G., McClelland, R.A., Burt, A.D., Fleming, K.A. N. Engl. J. Med. (1998) [Pubmed]
  12. Iron-chelation therapy with oral deferipronein patients with thalassemia major. Olivieri, N.F., Brittenham, G.M., Matsui, D., Berkovitch, M., Blendis, L.M., Cameron, R.G., McClelland, R.A., Liu, P.P., Templeton, D.M., Koren, G. N. Engl. J. Med. (1995) [Pubmed]
  13. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E., Harris, J.W. N. Engl. J. Med. (1994) [Pubmed]
  14. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St Louis, P., Freedman, M.H., McClelland, R.A., Templeton, D.M. Lancet (1990) [Pubmed]
  15. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Rustin, P., von Kleist-Retzow, J.C., Chantrel-Groussard, K., Sidi, D., Munnich, A., Rötig, A. Lancet (1999) [Pubmed]
  16. Cardioplegic arrest superimposed on evolving myocardial ischemia. Improved recovery after inhibition of hydroxyl radical generation by peroxidase or deferoxamine. A 31P nuclear resonance study. Bernard, M., Menasché, P., Piétri, S., Grousset, C., Piwnica, A., Cozzone, P.J. Circulation (1988) [Pubmed]
  17. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Wang, G.L., Semenza, G.L. Blood (1993) [Pubmed]
  18. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. Bronspiegel-Weintrob, N., Olivieri, N.F., Tyler, B., Andrews, D.F., Freedman, M.H., Holland, F.J. N. Engl. J. Med. (1990) [Pubmed]
  19. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. Weiss, G., Werner-Felmayer, G., Werner, E.R., Grünewald, K., Wachter, H., Hentze, M.W. J. Exp. Med. (1994) [Pubmed]
  20. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. Ghigo, D., Aldieri, E., Todde, R., Costamagna, C., Garbarino, G., Pescarmona, G., Bosia, A. J. Clin. Invest. (1998) [Pubmed]
  21. Acute iron poisoning. Rescue with macromolecular chelators. Mahoney, J.R., Hallaway, P.E., Hedlund, B.E., Eaton, J.W. J. Clin. Invest. (1989) [Pubmed]
  22. Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. Bridges, K.R., Smith, B.R. J. Clin. Invest. (1985) [Pubmed]
  23. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. Pan, M., Cederbaum, A.I., Zhang, Y.L., Ginsberg, H.N., Williams, K.J., Fisher, E.A. J. Clin. Invest. (2004) [Pubmed]
  24. Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. Byrd, T.F., Horwitz, M.A. J. Clin. Invest. (1989) [Pubmed]
  25. Clinical trial of desferrioxamine entrapped in red cell ghosts. Green, R., Lamon, J., Curran, D. Lancet (1980) [Pubmed]
  26. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. Schleicher, E.D., Wagner, E., Nerlich, A.G. J. Clin. Invest. (1997) [Pubmed]
  27. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Altmann, P., Plowman, D., Marsh, F., Cunningham, J. Lancet (1988) [Pubmed]
  28. Oxygen free radical injury of IEC-18 small intestinal epithelial cell monolayers. Ma, T.Y., Hollander, D., Freeman, D., Nguyen, T., Krugliak, P. Gastroenterology (1991) [Pubmed]
  29. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., Caro, J. Mol. Cell. Biol. (2002) [Pubmed]
  30. Iron regulates T-lymphocyte sensitivity to the IFN-gamma/STAT1 signaling pathway in vitro and in vivo. Regis, G., Bosticardo, M., Conti, L., De Angelis, S., Boselli, D., Tomaino, B., Bernabei, P., Giovarelli, M., Novelli, F. Blood (2005) [Pubmed]
  31. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mihaylova, V.T., Bindra, R.S., Yuan, J., Campisi, D., Narayanan, L., Jensen, R., Giordano, F., Johnson, R.S., Rockwell, S., Glazer, P.M. Mol. Cell. Biol. (2003) [Pubmed]
  32. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Camacho, M., López-Belmonte, J., Vila, L. Circ. Res. (1998) [Pubmed]
  33. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Shao, J., Zhou, B., Zhu, L., Qiu, W., Yuan, Y.C., Xi, B., Yen, Y. Cancer Res. (2004) [Pubmed]
  34. Reassessment of the use of desferrioxamine B in iron overload. Propper, R.D., Shurin, S.B., Nathan, D.G. N. Engl. J. Med. (1976) [Pubmed]
  35. Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis. Newman, S.L., Gootee, L., Brunner, G., Deepe, G.S. J. Clin. Invest. (1994) [Pubmed]
  36. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Hoffbrand, A.V., Gorman, A., Laulicht, M., Garidi, M., Economidou, J., Georgipoulou, P., Hussain, M.A., Flynn, D.M. Lancet (1979) [Pubmed]
  37. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis. Chang, T.M., Barre, P. Lancet (1983) [Pubmed]
WikiGenes - Universities